Synonyms: N-butyl-1-deoxynojirimycin | NB-DNJ | Zavesca®
miglustat is an approved drug (EMA (2002), FDA (2003))
Compound class:
Synthetic organic
Comment: Miglustat is a glucosylceramide synthase inhibitor. Marketed formulations may contain miglustat hydrochloride (PubChem CID 71299591).
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
References |
1. Butters TD, van den Broek LAGM, Fleet GWJ, Krulle TM, Wormald MR, Dwek RA, Platt FM. (2000)
Molecular requirements of imino sugars for the selective control of N-linked glycosylation and glycosphingolipid biosynthesis. Tetrahedron: Assymetry, 11 (1): 113-124. |
2. Voss AA, Díez-Sampedro A, Hirayama BA, Loo DD, Wright EM. (2007)
Imino sugars are potent agonists of the human glucose sensor SGLT3. Mol Pharmacol, 71 (2): 628-34. [PMID:17110502] |